Do analysts recommend JUNS or SCYX?

SCYNEXIS has a consensus price target of $24.00, indicating a potential upside of 439.33%. Given SCYNEXIS's stronger consensus rating and higher possible upside, analysts clearly believe SCYNEXIS is more favorable than Jupiter Neurosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend MRKR or JUNS?

Marker Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 584.93%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Marker Therapeutics is more favorable than Jupiter Neurosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marker Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate TXMD or JUNS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer TXMD or JUNS?

In the previous week, TherapeuticsMD and TherapeuticsMD both had 1 articles in the media. Jupiter Neurosciences' average media sentiment score of 0.76 beat TherapeuticsMD's score of 0.00 indicating that Jupiter Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TherapeuticsMD 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jupiter Neurosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate VYNE or JUNS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate JUNS or TPST?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is JUNS or TPST more profitable?

Tempest Therapeutics' return on equity of -355.61% beat Jupiter Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Jupiter Neurosciences N/A -1,314.62% -228.63% Tempest Therapeutics N/A -355.61% -121.21%

Does the media favor JUNS or TPST?

In the previous week, Tempest Therapeutics had 1 more articles in the media than Jupiter Neurosciences. MarketBeat recorded 2 mentions for Tempest Therapeutics and 1 mentions for Jupiter Neurosciences. Tempest Therapeutics' average media sentiment score of 0.99 beat Jupiter Neurosciences' score of 0.76 indicating that Tempest Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jupiter Neurosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tempest Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Jupiter Neurosciences (JUNS) Competitors

$0.23 -0.01 (-4.58%)

Closing price 06/8/2026 04:00 PM Eastern

Extended Trading

$0.24 +0.01 (+3.46%)

As of 04:20 AM Eastern

Compare

JUNS vs. SCYX, MRKR, TXMD, VYNE, and TPST

Should you buy Jupiter Neurosciences stock or one of its competitors? MarketBeat compares Jupiter Neurosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Jupiter Neurosciences include SCYNEXIS (SCYX), Marker Therapeutics (MRKR), TherapeuticsMD (TXMD), VYNE Therapeutics (VYNE), and Tempest Therapeutics (TPST). These companies are all part of the "med - drugs" industry.

How does Jupiter Neurosciences compare to SCYNEXIS?

Jupiter Neurosciences (NASDAQ:JUNS) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Jupiter Neurosciences has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -57.16% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%
SCYNEXIS	-41.79%	-57.16%	-39.48%

In the previous week, Jupiter Neurosciences had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 1 mentions for Jupiter Neurosciences and 0 mentions for SCYNEXIS. Jupiter Neurosciences' average media sentiment score of 0.76 beat SCYNEXIS's score of 0.00 indicating that Jupiter Neurosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Jupiter Neurosciences	Positive
SCYNEXIS	Neutral

Jupiter Neurosciences has a beta of 1.71, suggesting that its share price is 71% more volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

SCYNEXIS has a consensus price target of $24.00, indicating a potential upside of 439.33%. Given SCYNEXIS's stronger consensus rating and higher possible upside, analysts clearly believe SCYNEXIS is more favorable than Jupiter Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

54.4% of SCYNEXIS shares are held by institutional investors. 50.8% of Jupiter Neurosciences shares are held by company insiders. Comparatively, 4.1% of SCYNEXIS shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

SCYNEXIS has higher revenue and earnings than Jupiter Neurosciences. SCYNEXIS is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jupiter Neurosciences	$40.45K	207.20	-$8.65M	-$0.27	N/A
SCYNEXIS	$20.60M	1.21	-$8.61M	-$3.84	N/A

Summary

Jupiter Neurosciences and SCYNEXIS tied by winning 8 of the 16 factors compared between the two stocks.

How does Jupiter Neurosciences compare to Marker Therapeutics?

Marker Therapeutics (NASDAQ:MRKR) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Marker Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 584.93%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Marker Therapeutics is more favorable than Jupiter Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

22.4% of Marker Therapeutics shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by company insiders. Comparatively, 50.8% of Jupiter Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Marker Therapeutics has a beta of 1.44, indicating that its stock price is 44% more volatile than the broader market. Comparatively, Jupiter Neurosciences has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market.

Jupiter Neurosciences has lower revenue, but higher earnings than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	6.86	-$12.16M	-$0.61	N/A
Jupiter Neurosciences	$40.45K	207.20	-$8.65M	-$0.27	N/A

In the previous week, Jupiter Neurosciences had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 1 mentions for Jupiter Neurosciences and 0 mentions for Marker Therapeutics. Jupiter Neurosciences' average media sentiment score of 0.76 beat Marker Therapeutics' score of 0.00 indicating that Jupiter Neurosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Marker Therapeutics	Neutral
Jupiter Neurosciences	Positive

Jupiter Neurosciences has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-73.29%	-59.70%
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%

Summary

Jupiter Neurosciences beats Marker Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Jupiter Neurosciences compare to TherapeuticsMD?

TherapeuticsMD (NASDAQ:TXMD) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

30.7% of TherapeuticsMD shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by insiders. Comparatively, 50.8% of Jupiter Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, TherapeuticsMD and TherapeuticsMD both had 1 articles in the media. Jupiter Neurosciences' average media sentiment score of 0.76 beat TherapeuticsMD's score of 0.00 indicating that Jupiter Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TherapeuticsMD	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jupiter Neurosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TherapeuticsMD has a net margin of 5.34% compared to Jupiter Neurosciences' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%

TherapeuticsMD has higher revenue and earnings than Jupiter Neurosciences. Jupiter Neurosciences is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	7.20	-$570K	$0.06	31.33
Jupiter Neurosciences	$40.45K	207.20	-$8.65M	-$0.27	N/A

TherapeuticsMD has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market. Comparatively, Jupiter Neurosciences has a beta of 1.71, suggesting that its share price is 71% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

TherapeuticsMD beats Jupiter Neurosciences on 8 of the 12 factors compared between the two stocks.

How does Jupiter Neurosciences compare to VYNE Therapeutics?

VYNE Therapeutics (NASDAQ:VYNE) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

In the previous week, Jupiter Neurosciences had 1 more articles in the media than VYNE Therapeutics. MarketBeat recorded 1 mentions for Jupiter Neurosciences and 0 mentions for VYNE Therapeutics. Jupiter Neurosciences' average media sentiment score of 0.76 beat VYNE Therapeutics' score of 0.00 indicating that Jupiter Neurosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
VYNE Therapeutics	Neutral
Jupiter Neurosciences	Positive

VYNE Therapeutics has a beta of 2, suggesting that its stock price is 100% more volatile than the broader market. Comparatively, Jupiter Neurosciences has a beta of 1.71, suggesting that its stock price is 71% more volatile than the broader market.

Jupiter Neurosciences has lower revenue, but higher earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$570K	38.53	-$26.48M	-$0.38	N/A
Jupiter Neurosciences	$40.45K	207.20	-$8.65M	-$0.27	N/A

Jupiter Neurosciences has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%

83.8% of VYNE Therapeutics shares are owned by institutional investors. 3.0% of VYNE Therapeutics shares are owned by insiders. Comparatively, 50.8% of Jupiter Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Jupiter Neurosciences beats VYNE Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Jupiter Neurosciences compare to Tempest Therapeutics?

Jupiter Neurosciences (NASDAQ:JUNS) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

22.5% of Tempest Therapeutics shares are owned by institutional investors. 50.8% of Jupiter Neurosciences shares are owned by insiders. Comparatively, 6.3% of Tempest Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Tempest Therapeutics had 1 more articles in the media than Jupiter Neurosciences. MarketBeat recorded 2 mentions for Tempest Therapeutics and 1 mentions for Jupiter Neurosciences. Tempest Therapeutics' average media sentiment score of 0.99 beat Jupiter Neurosciences' score of 0.76 indicating that Tempest Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jupiter Neurosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tempest Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Jupiter Neurosciences has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.85, indicating that its share price is 285% less volatile than the broader market.

Jupiter Neurosciences has higher revenue and earnings than Tempest Therapeutics. Jupiter Neurosciences is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jupiter Neurosciences	$40.45K	207.20	-$8.65M	-$0.27	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A

Tempest Therapeutics' return on equity of -355.61% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%
Tempest Therapeutics	N/A	-355.61%	-121.21%

Summary

Tempest Therapeutics beats Jupiter Neurosciences on 7 of the 12 factors compared between the two stocks.

Get Jupiter Neurosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JUNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JUNS vs. The Competition

Export

Metric	Jupiter Neurosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.78M	$2.96B	$6.48B	$11.99B
Dividend Yield	N/A	1.70%	2.67%	5.58%
P/E Ratio	-0.86	17.68	23.69	23.74
Price / Sales	207.20	302.68	514.83	109.27
Price / Cash	N/A	56.17	26.99	37.25
Price / Book	-4.62	3.83	10.43	6.78
Net Income	-$8.65M	$75.85M	$3.57B	$337.51M
7 Day Performance	-17.00%	-2.00%	0.27%	-2.34%
1 Month Performance	-30.59%	-5.85%	3.25%	1.88%
1 Year Performance	-70.40%	14.03%	22.24%	25.55%

Jupiter Neurosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
JUNS Jupiter Neurosciences	0.7515 of 5 stars	$0.23 -4.6%	N/A	-70.4%	$8.78M	$40.45K	N/A	5
SCYX SCYNEXIS	1.6119 of 5 stars	$4.67 -8.4%	$24.00 +413.9%	-39.4%	$26.07M	$20.34M	N/A	60
MRKR Marker Therapeutics	1.77 of 5 stars	$1.45 +2.1%	$10.00 +589.7%	-17.5%	$24.17M	$3.55M	N/A	60
TXMD TherapeuticsMD	1.0099 of 5 stars	$1.97 -3.4%	N/A	+50.4%	$22.79M	$3.02M	32.83	420
VYNE VYNE Therapeutics	0.6437 of 5 stars	$0.66 -3.0%	N/A	-34.1%	$21.88M	$570K	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JUNS) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jupiter Neurosciences (JUNS) Competitors

JUNS vs. SCYX, MRKR, TXMD, VYNE, and TPST

How does Jupiter Neurosciences compare to SCYNEXIS?

Summary

How does Jupiter Neurosciences compare to Marker Therapeutics?

Summary

How does Jupiter Neurosciences compare to TherapeuticsMD?

Summary

How does Jupiter Neurosciences compare to VYNE Therapeutics?

Summary

How does Jupiter Neurosciences compare to Tempest Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JUNS vs. The Competition

Jupiter Neurosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jupiter Neurosciences (JUNS) Competitors

JUNS vs. SCYX, MRKR, TXMD, VYNE, and TPST

How does Jupiter Neurosciences compare to SCYNEXIS?

Is JUNS or SCYX more profitable?

Does the media refer more to JUNS or SCYX?

Which has more risk and volatility, JUNS or SCYX?

Do analysts recommend JUNS or SCYX?

Do institutionals & insiders believe in JUNS or SCYX?

Which has preferable valuation and earnings, JUNS or SCYX?

Summary

How does Jupiter Neurosciences compare to Marker Therapeutics?

Do analysts recommend MRKR or JUNS?

Do insiders and institutionals believe in MRKR or JUNS?

Which has more risk and volatility, MRKR or JUNS?

Which has higher valuation & earnings, MRKR or JUNS?

Does the media prefer MRKR or JUNS?

Is MRKR or JUNS more profitable?

Summary

How does Jupiter Neurosciences compare to TherapeuticsMD?

Do institutionals and insiders hold more shares of TXMD or JUNS?

Does the media prefer TXMD or JUNS?

Is TXMD or JUNS more profitable?

Which has higher valuation & earnings, TXMD or JUNS?

Which has more risk and volatility, TXMD or JUNS?

Do analysts rate TXMD or JUNS?

Summary

How does Jupiter Neurosciences compare to VYNE Therapeutics?

Does the media favor VYNE or JUNS?

Which has more risk and volatility, VYNE or JUNS?

Which has better valuation & earnings, VYNE or JUNS?

Is VYNE or JUNS more profitable?

Do insiders and institutionals hold more shares of VYNE or JUNS?

Do analysts rate VYNE or JUNS?

Summary

How does Jupiter Neurosciences compare to Tempest Therapeutics?

Do analysts rate JUNS or TPST?

Do insiders & institutionals hold more shares of JUNS or TPST?

Does the media favor JUNS or TPST?

Which has more risk and volatility, JUNS or TPST?

Which has better valuation and earnings, JUNS or TPST?

Is JUNS or TPST more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JUNS vs. The Competition

Jupiter Neurosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools